Navigating Europe's AI regulatory labyrinth: A strategic gui...
For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.
Newsletters and Deep Dive digital magazine
For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.
Capturing data digitally at source can significantly reduce the workflow for sites, yet, implementing it across studies has been rather unattainable.
For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.
Behaviour is the layer that lifestyle, physical performance, and nutrition – together – occupy.
Editor's Picks
Newsletters and Deep Dive
digital magazine